3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Carcinoma, Non-Small-Cell Lung
9
Lung Neoplasms
7
Breast Neoplasms
5
Glioma
4
Glioblastoma
4
Neoplasms
3
Gliosarcoma
3
Urinary Bladder Neoplasms
2
Stomach Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Pancreatic Neoplasms
2
Neoplasm Metastasis
2
Esophageal Neoplasms
2
Colorectal Neoplasms
2
Brain Neoplasms
2
Urethral Neoplasms
1
Ureteral Neoplasms
1
Unspecified Adult Solid Tumor, Protocol Specific
1
Thyroid cancer, medullary
1
Thyroid Neoplasms
1
Thyroid Diseases
1
Thyroid Cancer, Papillary
1
Small Cell Lung Carcinoma
1
Relapsed Pediatric Solid Tumor
1
Recurrence
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Precancerous Conditions
1
Pleural Effusion
1
Pheochromocytoma
1
Interventions
Pemetrexed
4
pembrolizumab
3
Carboplatin
3
Vinorelbine
2
Gemcitabine
2
vistusertib
1
vandetanib
1
spartalizumab
1
sotorasib
1
sintilimab
1
olaparib
1
icotinib
1
durvalumab
1
dacomitinib
1
capivasertib
1
aumolertinib
1
Radiosurgery
1
Platinum
1
MLN 8237
1
Injections
1
Immune Checkpoint Inhibitors
1
Gefitinib
1
GC Temporary Stopping
1
Erlotinib Hydrochloride
1
Drug Therapy
1
Cisplatin
1
Bevacizumab
1
AZD4547
1
AZD 8931
1
AZD 6244
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Non-small Cell Lung Cancer Metastatic
×
vandetanib
×
Clear all
NCT02117167
2024-01-10
SAFIR02_Lung
UNICANCER
Phase 2
Completed
999 enrolled